NSC 651016
Latest Information Update: 30 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial sources
- Class Antivirals; Naphthalenesulfonates
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Graft-versus-host disease; HIV infections
Most Recent Events
- 01 May 2000 Preclinical development for Graft-versus-host disease in USA (Parenteral)
- 01 May 2000 An in vitro study has been added to the pharmacodynamis section of transplant rejection (816659
- 15 Oct 1998 Preclinical development for HIV infections prevention in USA (Vaginal)